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108Objective: Patients who require aortic valve replacement are increasingly receiving biologic valves to avoid
long-term anticoagulation. The thromboembolic risk of bioprosthetic valves is reportedly low. The study objec-
tive was to review the incidence of early valve thrombosis requiring reoperation in patients who received a bio-
prosthetic valve in the aortic position.
Methods: We reviewed all adult patients who had a biologic valve implanted in the aortic position at Mayo
Clinic between January 1993 and July 2009. Records were reviewed for all cases of reoperation that occurred
less than 2 years postoperatively. Incidences of valve thrombosis were calculated including 95% Poisson con-
fidence intervals.
Results:During the study interval, 4568 patients received biologic valves for aortic valve replacement. We iden-
tified 8 patients who underwent reoperation to replace the aortic prosthesis because of thrombus that resulted in
functional aortic stenosis. The median age of patients at the time of reoperation was 77 years (range, 52–86), and
the median time to reoperation was 398 days (range, 106–626). All patients with valve thrombosis received
a stented porcine valve: St Jude Biocor (St Jude Medical, Inc, St Paul, Minn) in 4 patients, Medtronic Mosaic
(Medtronic Inc, Minneapolis, Minn) in 2 patients, and Medtronic Hancock (Medtronic Inc) in 2 patients. The
calculated incidence of valve thrombosis was 1.26% (confidence interval, 0.56–1.96) for the Biocor valve,
0.37% (confidence interval, 0.19–0.56) for the Mosaic valve, and 0.84% (confidence interval, 0.42–1.25) for
the Hancock valve (P ¼ .34). There were no cases of valve thrombosis in patients who received a pericardial
valve (5923 patient-years) or stentless valve (172 patient-years).
Conclusions: The incidence of early thrombosis of porcine aortic bioprostheses requiring reoperation was not
insignificant. Potential causes and mechanisms for such thrombosis are unknown. Recognition of this unantic-
ipated problem and reoperation resulted in a satisfactory outcome for patients. (J Thorac Cardiovasc Surg
2012;144:108-11)Patients who require aortic valve replacement are increas-
ingly receiving biologic valves rather than mechanical
valves to avoid long-term anticoagulation and its potential
complications.1-3 Although risk of thromboembolic events
after bioprosthetic aortic valve replacement is higher in
the first 3 months than later,4,5 recent studies suggest that
early anticoagulation in low-risk patients does not signifi-
cantly decrease the incidence of thromboembolism.6-8
In a meta-analysis based on microsimulation, Puvimana-
singhe and colleagues9 estimated the linearized occurrence
rate of thrombosis for an aortic valve bioprosthesis to be
0.03 events per 100 patient-years, but this estimate is based
on only 3 events in 9925 patient-years of follow-up. Wee Department of Anesthesiology and Pain Medicine,a University of Alberta,
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The Journal of Thoracic and Cardiovascular Surgrecently observed several cases of symptomatic early
thrombosis of bioprosthetic valves. Our objective was to re-
view the incidence of reoperation for early valve thrombosis
in patients who received a bioprosthetic valve in the aortic
position.MATERIALS AND METHODS
After institutional review board approval, we reviewed adult patients
(>18 years) who had a biologic valve implanted in the aortic position at
Mayo Clinic (Rochester, Minn). Patient records and follow-up surveys
were used to identify all cases of reoperation less than 2 years after implan-
tation of the biologic valve. Medical records and pathology reports were re-
viewed for evidence of thrombosis as a mechanism of failure. Patients who
had pannus, structural valve deterioration such as tears, or any evidence of
infection were excluded. The incidence of thrombosis and per patient-year
were calculated, along with the Poisson 95% confidence interval using
StatsDirect (2007). Groups were compared using the Fisher exact test.RESULTS
From January 1, 1993, to July 1, 2009, 4568 biologic
valves were implanted in the aortic position in adult pa-
tients. Of these, 3031 were stented pericardial, 1463 were
stented porcine, and 74 were stentless porcine valves.
We identified 8 patients (0.18%) who underwent reoper-
ation for thrombosis of a biologic aortic valve. The medianery c July 2012
FIGURE 1. A, The aortic valve has been explanted, and there is extensive
thrombus present in the cusps on the aortic side of the valve. B, The ven-
tricular side of the valve was spared.
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2007 (range, 1999–2007), and the median valve size was
23 mm (range, 21–27 mm). At the time of reoperation for
the thrombosed valve, the median patient age was 77 years
(range, 52–86 years). The median interval between the
original implant and the reoperation was 398 days (range,
106–626 days). All patients presented with symptoms, in-
cluding shortness of breath, chest pain, or fatigue. No pa-
tients were hemodynamically unstable from the valve
thrombosis. In all cases, echocardiography diagnosed pros-
thetic valve stenosis as moderate-severe or severe. Two pa-
tients also had mild aortic regurgitation.
The incidence of thrombosis was calculated for each
valve type (Table 1). The St Jude Biocor (St Jude Medical,
Inc, St Paul, Minn) valve had an incidence of 1.26%, the
Medtronic Hancock (Medtronic Inc, Minneapolis, Minn)
valve had an incidence of 0.84%, and theMedtronicMosaic
(Medtronic Inc) valve had an incidence of 0.37%. These are
all stented porcine valves. There was no difference in the in-
cidence of thrombosis among the 3 valve types (P ¼ .34).
Overall, stented porcine valves had an incidence of
0.55%. There were no cases of thrombosis in stented peri-
cardial valves or stentless porcine valves. On comparison of
incidences among valve types, therewas a significant differ-
ence between the stented porcine and pericardial valves
(P<.001). There was no statistically demonstrable differ-
ence between the stented porcine and stentless porcine
valves, likely because of the small number of patients in
the stentless group (P>.05).
Pathology reports identified thrombus on the aortic side
of the valve in all cases (Figure 1). There was minimal
clot present on the ventricular side of the valves. In 1 pa-
tient, a small amount of focal calcification was present on
one of the valve leaflets. There was no evidence of other
causes of structural valve deterioration (eg, tears or perfora-
tion) or endocarditis in all cases. Pledgets were placed in all
patients.
Patient characteristics that were postulated to be con-
tributing factors were examined, including factors that
could contribute to a change in the flow of blood past
the aortic valve. The median postoperative aortic valve
gradient after the original aortic valve replacement was
26 mm Hg (range, 13–35 mm Hg), and the medianTABLE 1. Incidence of valve thrombosis
N Inciden
Stented porcine 1463
St Jude Biocor (St Jude Medical, Inc, St Paul, Minn) 318
Medtronic Mosaic (Medtronic Inc, Minneapolis, Minn) 541
Medtronic Hancock (Medtronic Inc) 270
Stented pericardial 3031
Stentless 74
CI, Confidence interval.
The Journal of Thoracic and Capostoperative ejection fraction was 49% (range, 23%–
70%). No patients had a perivalvular leak. Interval echo-
cardiograms were not available for all patients. Valves
were implanted by a number of different surgeons and
surgical teams, and each implanted both porcine and
pericardial prostheses. No patients showed evidence of
endocarditis at any time, including positive blood cul-
tures or fever.
All patients received aspirin therapy early after surgery
and in follow-up. Only 3 of 8 patients received warfarin
for the first 3 months postoperatively. On the basis of
the clinical assessments and laboratory investigationsce of thrombosis
95% CI of the incidence
of thrombosis
Rate of thrombosis
(per patient year)
0.55%
1.26% 0.56–1.96 0.70%
0.37% 0.19–0.56 0.19%
0.84% 0.42–1.25 0.41%
0% 0 0
0% 0–0.3 0
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FIGURE 2. Porcine valves share a common design feature dictated by at-
tachment of the leaflet to the stent, which is a ‘‘rail’’ that could promote sta-
sis of blood in the belly of the leaflet. Pericardial valves have no rail.
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Dthat were available, none of the 8 patients had an identifi-
able thrombophilia; however, complete workups were not
available on all patients. One patient was found to have re-
nal cell carcinoma during the workup for the valve throm-
bosis. No other patients were known to have active cancer
or developed cancer in the 6 months after aortic valve
thrombosis.
All 8 patients survived reoperation. Five patients received
amechanical valve and 3 patients received a stented pericar-
dial valve at the time of reoperation. No patients have re-
turned with thrombosis subsequently (median follow-up,
457 days; range, 10–3238 days).
DISCUSSION
We observed 8 reoperations secondary to valve thrombo-
sis within 2 years of implantation of a stented porcine valve
in the aortic position. The incidence of thrombosis in
stented porcine valves ranged between 0.19% per patient
year for the Medtronic Mosaic and 0.70% per patient
year for the St Jude Biocor. No patients with pericardial
valves experienced thrombosis.
The incidence of porcine prosthetic valve thrombosis re-
ported in this article is significantly higher than that reported
previously. One study estimated the incidence of valve
thrombosis in porcine valves at 0.03% per patient year using
a simulation model based on the available reported liter-
ature.9 There have been several case reports and small
case series of early thromboses of porcine valves.5,10-14
It is difficult to assess the rate of valve thrombosis in
most publications, because thromboembolism is most
often reported, not valve thrombosis. Nevertheless, the
event rate of early porcine valve thrombosis requiring
reoperation is not clinically insignificant in our experience.
In regard to stented pericardial valves, there is one re-
ported case of early thrombosis in a Carpentier-Edwards
(Edwards Lifesciences LLC, Irvine, Calif) 19-mm pericar-
dial valve placed in the aortic position.15 This patient died
of sudden cardiac arrest on postoperative day 6 and was
found to have thrombus on the aortic aspect of the prosthesis
that resulted in occlusion of the valve. This patient was not
taking any anticoagulation at the time and had no known
risk factors for thrombosis. We did not encounter any pa-
tient with early valve thrombosis of a pericardial valve.
It is unknown whether there are risk factors specific for
early valve thrombosis, because the reports are too small
to make any meaningful inferences. It can be presumed
that any hypercoaguable state may predispose to formation
of thrombus on a foreign valve. Other contributing factors
may be low ejection fraction, small valve size, or presence
of perivalvular leak, early pannus, or endocarditis. All these
factors may not allow for adequate washing of the valve
leaflets, may cause turbulence around the valve, and may
lead to thrombosis in a predisposed patient. Although we
do not have direct evidence for an impact of valve design110 The Journal of Thoracic and Cardiovascular Surgon the risk of thrombosis, the porcine valves all have a de-
sign that includes a ‘‘rail’’ in the sinus portions (Figure 2)
that could conceivably inhibit leaflet washing by creating
a ‘bowl’’ around the leaflet. This could contribute to stasis
and leaflet thrombosis. Thrombosis may be related to a dif-
ference in valve materials.
Whether early anticoagulation with warfarin or platelet
antagonists, such as aspirin or clopidogrel, may prevent
valve thrombosis is unknown. Anticoagulation in low-risk
patients receiving an aortic bioprostheses did not decrease
the incidence of thromboembolism in several studies.6-8
Nevertheless, it should be noted that valve thrombosis is
such a rare event that it would be difficult to determine
whether any therapy could be preventative and what
duration of therapy would be necessary.
There are limited published data to guide the surgeon
in the choice of prosthesis to be placed at the second op-
eration after a case of porcine valve thrombosis. Because
we have not had any cases of early valve thrombosis re-
quiring reoperation in a pericardial valve implanted in the
aortic position, it seems reasonable that a mechanical or
pericardial valve could be used. This should be guided
by the patient’s preference after a full discussion of the
issues.
This is an observational study and is subject to all the
limitations of this study design. Valve thrombosis is de-
fined in the literature as any thrombus not caused by in-
fection attached to or near an operated valve that
occludes part of the blood flow path, interferes with valve
function, or is sufficiently large to warrant treatment.16
However, because of the study design, we cannot account
for the patients who may have required treatment with
anticoagulants for valve thrombosis. We did review all
available follow-up information for medically treated
thromboses, but we did not identify any other cases of
thromboses.ery c July 2012
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DCONCLUSIONS
The incidence of early thrombosis of porcine aortic bi-
oprostheses requiring reoperation was not insignificant.
Potential causes and mechanisms for such thrombosis
are unknown. Recognition of this unanticipated problem
and reoperation resulted in a satisfactory outcome for
patients.
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